Biotech Values

[gta888]

They would have to dilute more in current market conditions IMHO and would go against prior mgmt points about capital raises. Why do that when we are still in a yield hungry environment. It's a win win situation for the institution as they have lower convert pricing in the event the stock starts to move and continue their income stream. If reduce it, spa, anchor or nce issue catalysts turn positive....$2.86 would be easy. Better than refinancing at higher short rates in the future. I would say the convert news dropped the stock 10% today....had they done an offering! they would need to sell for at least 25% discount with all the litigation and FDA related drama.